EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
Phase of Trial: Phase IV
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Adverse reactions
- Acronyms EXPERT
- Sponsors Bayer
- 23 Jul 2018 Status changed from active, no longer recruiting to completed.
- 23 May 2018 Interim safety results (n=1249; Data cut-off; June 15, 2017) presented at the 114th International Conference of the American Thoracic Society
- 11 Apr 2018 Planned primary completion date changed from 31 Mar 2018 to 19 Jun 2018.